$MGTX
MeiraGTx Holdings plc Stock $mgtx

$mgtx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000155837022013192 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$4.816M	$10.76M	$5.633M
YoY Change	-30.68%	110.3%	22.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.76M	$10.52M	$11.27M
YoY Change	36.45%	1.05%	13.59%
% of Gross Profit
Research & Development	$16.86M	$24.00M	$23.10M
YoY Change	-21.98%	57.99%	38.24%
% of Gross Profit
Depreciation & Amortization	$2.028M	$2.085M	$2.118M
YoY Change	-0.44%	3.53%	20.48%
% of Gross Profit
Operating Expenses	$27.62M	$34.52M	$34.37M
YoY Change	-6.36%	34.84%	29.07%
Operating Profit	-$22.81M	-$23.76M	-$28.73M
YoY Change	1.14%	15.99%	30.42%
Interest Expense	$1.892M	$82.00K	$77.00K
YoY Change	3106.78%	60.78%	30.51%
% of Operating Profit
Other Income/Expense, Net	-$75.00K	$210.0K	$355.0K
YoY Change	97.37%	-638.46%	-987.5%
Pretax Income	-$37.28M	-$33.97M	-$31.05M
YoY Change	43.7%	69.14%	31.44%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$37.28M	-$33.97M	-$31.05M
YoY Change	43.7%	69.14%	31.45%
Net Earnings / Revenue	-774.17%	-315.76%	-551.13%
Basic Earnings Per Share	-$0.83	-$0.76	-$0.70
Diluted Earnings Per Share	-$0.83	-$0.76	-$0.70
COMMON SHARES
Basic Shares Outstanding	44.71M	44.67M	44.50M
Diluted Shares Outstanding	44.69M	44.67M	44.50M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.7M	$72.11M	$113.8M
YoY Change	-20.14%	-58.21%	-42.94%
Cash & Equivalents	$114.7M	$72.11M	$113.8M
Short-Term Investments
Other Short-Term Assets	$1.561M	$3.330M	$1.984M
YoY Change	-32.1%	28.67%	-59.9%
Inventory
Prepaid Expenses	$10.17M	$6.682M	$7.217M
Receivables	$23.70M	$15.94M	$13.08M
Other Receivables	$4.897M	$6.350M	$6.865M
Total Short-Term Assets	$155.0M	$104.4M	$142.9M
YoY Change	-12.37%	-49.57%	-37.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$93.62M	$91.39M	$84.07M
YoY Change	46.97%	67.14%	77.72%
Goodwill
YoY Change
Intangibles	$1.293M	$1.474M	$1.668M
YoY Change	-30.52%	-26.08%	-19.03%
Long-Term Investments	$6.656M	$6.656M	$6.656M
YoY Change	-0.14%	-0.14%	-0.66%
Other Assets	$1.322M	$1.505M	$1.609M
YoY Change	557.71%	630.58%	688.73%
Total Long-Term Assets	$146.4M	$148.0M	$144.8M
YoY Change	15.8%	23.66%	32.15%
TOTAL ASSETS
Total Short-Term Assets	$155.0M	$104.4M	$142.9M
Total Long-Term Assets	$146.4M	$148.0M	$144.8M
Total Assets	$301.4M	$252.5M	$287.7M
YoY Change	-0.63%	-22.74%	-15.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.69M	$18.11M	$18.50M
YoY Change	89.94%	55.54%	134.09%
Accrued Expenses	$24.77M	$23.57M	$23.18M
YoY Change	12.99%	34.24%	34.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$72.36M	$67.51M	$65.50M
YoY Change	21.35%	17.91%	22.39%
LONG-TERM LIABILITIES
Long-Term Debt	$70.85M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$35.36M	$42.80M	$60.71M
YoY Change	-36.47%	-32.69%	-6.88%
Total Long-Term Liabilities	$106.2M	$42.80M	$60.71M
YoY Change	90.8%	-32.69%	-6.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$72.36M	$67.51M	$65.50M
Total Long-Term Liabilities	$106.2M	$42.80M	$60.71M
Total Liabilities	$178.7M	$110.5M	$126.4M
YoY Change	54.76%	-8.72%	6.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$442.9M	-$405.6M	-$371.6M
YoY Change	33.93%	33.11%	30.57%
Common Stock	$2.000K	$2.000K	$2.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$122.7M	$142.0M	$161.3M
YoY Change
Total Liabilities & Shareholders Equity	$301.4M	$252.5M	$287.7M
YoY Change	-0.63%	-22.74%	-15.3%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$37.28M	-$33.97M	-$31.05M
YoY Change	43.7%	69.14%	31.45%
Depreciation, Depletion And Amortization	$2.028M	$2.085M	$2.118M
YoY Change	-0.44%	3.53%	20.48%
Cash From Operating Activities	-$20.73M	-$27.81M	-$8.300M
YoY Change	20.62%	30.76%	-191.35%
INVESTING ACTIVITIES
Capital Expenditures	-$10.01M	-$14.00M	$12.46M
YoY Change	-15.91%	151.03%	176.77%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$10.01M	-$14.00M	-$12.46M
YoY Change	-15.91%	151.21%	-33.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$2.774M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	72.95M	0.000	-2.582M
YoY Change	134990.74%	-100.0%	-1998.53%
NET CHANGE
Cash From Operating Activities	-20.73M	-27.81M	-8.300M
Cash From Investing Activities	-10.01M	-14.00M	-12.46M
Cash From Financing Activities	72.95M	0.000	-2.582M
Net Change In Cash	42.21M	-41.81M	-23.34M
YoY Change	-245.39%	57.06%	141.99%
FREE CASH FLOW
Cash From Operating Activities	-$20.73M	-$27.81M	-$8.300M
Capital Expenditures	-$10.01M	-$14.00M	$12.46M
Free Cash Flow	-$10.72M	-$13.81M	-$20.76M
YoY Change	103.01%	-11.99%	-552.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	3330000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2420000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6682000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8102000
CY2022Q2	mgtx	Tax Incentive Receivable TaxIncentiveReceivable	6350000
CY2021Q4	mgtx	Tax Incentive Receivable TaxIncentiveReceivable	12634000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	104412000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	183243000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91388000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75860000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1474000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
	dei	Entity Central Index Key EntityCentralIndexKey	0001735438
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44668240
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44137773
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44585239
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44056535
CY2022Q2	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2022Q2	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44548925
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44710678
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38520
	dei	Entity Registrant Name EntityRegistrantName	MeiraGTx Holdings plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1448305
	dei	Entity Address Address Line1 EntityAddressAddressLine1	450 East 29th Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	14th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10016
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	860-7985
	dei	Security12b Title Security12bTitle	Ordinary Shares,$0.00003881 par value per share
	dei	Trading Symbol TradingSymbol	MGTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44710678
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72108000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137703000
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	15942000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	22384000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6682000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8102000
CY2022Q2	mgtx	Tax Incentive Receivable TaxIncentiveReceivable	6350000
CY2021Q4	mgtx	Tax Incentive Receivable TaxIncentiveReceivable	12634000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	3330000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2420000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	104412000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	183243000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91388000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75860000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1474000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1791000
CY2022Q2	mgtx	In Process Research And Development InProcessResearchAndDevelopment	723000
CY2021Q4	mgtx	In Process Research And Development InProcessResearchAndDevelopment	783000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1505000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1404000
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	6656000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	6656000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21538000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22782000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24765000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	27645000
CY2022Q2	us-gaap	Assets Assets	252461000
CY2021Q4	us-gaap	Assets Assets	320164000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	18111000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27586000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3634000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3374000
CY2022Q2	mgtx	Deferred Revenue Related Party Current DeferredRevenueRelatedPartyCurrent	21205000
CY2021Q4	mgtx	Deferred Revenue Related Party Current DeferredRevenueRelatedPartyCurrent	21820000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	983000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	67505000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	68128000
CY2022Q2	mgtx	Deferred Revenue Related Party Noncurrent DeferredRevenueRelatedPartyNoncurrent	21337000
CY2021Q4	mgtx	Deferred Revenue Related Party Noncurrent DeferredRevenueRelatedPartyNoncurrent	43046000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19063000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20359000
CY2022Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2099000
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2081000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	181000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	196000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1791000
CY2022Q2	mgtx	In Process Research And Development InProcessResearchAndDevelopment	723000
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	6656000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	6656000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21538000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22782000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24765000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	27645000
CY2022Q2	us-gaap	Assets Assets	252461000
CY2021Q4	us-gaap	Assets Assets	320164000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	18111000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15348000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23572000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27586000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3634000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3374000
CY2022Q2	mgtx	Deferred Revenue Related Party Current DeferredRevenueRelatedPartyCurrent	21205000
CY2021Q4	mgtx	Deferred Revenue Related Party Current DeferredRevenueRelatedPartyCurrent	21820000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	983000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	67505000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	68128000
CY2022Q2	mgtx	Deferred Revenue Related Party Noncurrent DeferredRevenueRelatedPartyNoncurrent	21337000
CY2021Q4	mgtx	Deferred Revenue Related Party Noncurrent DeferredRevenueRelatedPartyNoncurrent	43046000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19063000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20359000
CY2022Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2099000
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2081000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	181000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	196000
CY2022Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	304000
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	953000
CY2022Q2	us-gaap	Liabilities Liabilities	110489000
CY2021Q4	us-gaap	Liabilities Liabilities	134763000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44710678
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44548925
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	540958000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	528659000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6619000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2671000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405607000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-340589000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	141972000
CY2022Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	304000
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	953000
CY2022Q2	us-gaap	Liabilities Liabilities	110489000
CY2021Q4	us-gaap	Liabilities Liabilities	134763000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44710678
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44548925
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	540958000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	528659000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6619000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2671000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405607000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-340589000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	141972000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	185401000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	320164000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10759000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5116000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16392000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9711000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10518000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10409000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21786000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20327000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23999000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15190000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47098000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31900000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	34517000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	25599000
	us-gaap	Operating Expenses OperatingExpenses	68884000
	us-gaap	Operating Expenses OperatingExpenses	52227000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23758000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20483000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52492000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42516000
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10426000
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	381000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13073000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1234000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	41000
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	67000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	185401000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	252461000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	320164000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10759000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5116000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16392000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9711000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10518000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10409000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21786000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20327000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23999000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15190000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47098000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31900000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	34517000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	25599000
	us-gaap	Operating Expenses OperatingExpenses	68884000
	us-gaap	Operating Expenses OperatingExpenses	52227000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23758000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20483000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52492000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42516000
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10426000
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	381000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13073000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1234000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	41000
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	67000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	156000
CY2022Q2	us-gaap	Interest Expense InterestExpense	82000
CY2021Q2	us-gaap	Interest Expense InterestExpense	51000
	us-gaap	Interest Expense InterestExpense	159000
	us-gaap	Interest Expense InterestExpense	110000
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	252000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	649000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-33973000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-20086000
	us-gaap	Net Income Loss NetIncomeLoss	-65018000
	us-gaap	Net Income Loss NetIncomeLoss	-43704000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7357000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-407000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9290000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-678000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26616000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20493000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55728000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65018000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	156000
CY2022Q2	us-gaap	Interest Expense InterestExpense	82000
CY2021Q2	us-gaap	Interest Expense InterestExpense	51000
	us-gaap	Interest Expense InterestExpense	159000
	us-gaap	Interest Expense InterestExpense	110000
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	252000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	649000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-33973000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-20086000
	us-gaap	Net Income Loss NetIncomeLoss	-65018000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-407000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9290000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-678000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26616000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20493000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55728000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44382000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33973000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20086000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65018000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-43704000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44668240
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44137773
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44585239
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44056535
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	185401000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4996000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1933000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31045000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	161285000
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7303000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7357000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-33973000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	141972000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	238559000
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4958000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1165000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-271000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-23618000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	220793000
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5422000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-407000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-20086000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	205722000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-43704000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44668240
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44137773
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44585239
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44056535
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	185401000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4996000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1933000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31045000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	161285000
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7303000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7357000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-33973000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	141972000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	238559000
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4958000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1165000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-271000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16392000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-23618000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	220793000
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5422000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-407000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-20086000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	205722000
	us-gaap	Profit Loss ProfitLoss	-65018000
	us-gaap	Profit Loss ProfitLoss	-43704000
	us-gaap	Share Based Compensation ShareBasedCompensation	14881000
	us-gaap	Share Based Compensation ShareBasedCompensation	10020000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13073000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1234000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4203000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3774000
	mgtx	Operating Leases Expenses OperatingLeasesExpenses	-98000
	mgtx	Operating Leases Expenses OperatingLeasesExpenses	95000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	84000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	74000
	mgtx	Change In Acquisition Liability ChangeInAcquisitionLiability	-649000
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-5794000
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-20666000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1009000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-620000
	mgtx	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-5565000
	mgtx	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-5667000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1096000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2163000
	us-gaap	Profit Loss ProfitLoss	-65018000
	us-gaap	Profit Loss ProfitLoss	-43704000
	us-gaap	Share Based Compensation ShareBasedCompensation	14881000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13073000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3774000
	mgtx	Operating Leases Expenses OperatingLeasesExpenses	-98000
	mgtx	Operating Leases Expenses OperatingLeasesExpenses	95000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	84000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	74000
	mgtx	Change In Acquisition Liability ChangeInAcquisitionLiability	-649000
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-5794000
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-20666000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1009000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-620000
	mgtx	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-5565000
	mgtx	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-5667000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1096000
	mgtx	Increase Decrease In Other Assets IncreaseDecreaseInOtherAssets	521000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3706000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2519000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1058000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5048000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-23000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-9711000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36105000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12175000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26460000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10077000
	mgtx	Payments For Right Of Use Asset PaymentsForRightOfUseAsset	8866000
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5500000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	192000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	360000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-2774000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	359000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-65147000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-706000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137703000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	172555000
	mgtx	Stock Issued Under License Agreement StockIssuedUnderLicenseAgreement	1165000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	7484000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	3184000
	mgtx	Lease Obligations In Exchange Of Right Of Use Assets LeaseObligationsInExchangeOfRightOfUseAssets	-1793000
	mgtx	Lease Obligations In Exchange Of Right Of Use Assets LeaseObligationsInExchangeOfRightOfUseAssets	-4123000
	us-gaap	Asset Retirement Obligation Period Increase Decrease AssetRetirementObligationPeriodIncreaseDecrease	9000
	us-gaap	Interest Paid Net InterestPaidNet	75000
	us-gaap	Interest Paid Net InterestPaidNet	35000
	mgtx	No.Of Programs In Clinical Development No.OfProgramsInClinicalDevelopment	6
	mgtx	Increase Decrease In Other Assets IncreaseDecreaseInOtherAssets	109000
	mgtx	Increase Decrease In Other Assets IncreaseDecreaseInOtherAssets	521000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3706000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2519000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1058000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5048000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-23000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16392000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-9711000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36105000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12175000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26460000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10077000
	mgtx	Payments For Right Of Use Asset PaymentsForRightOfUseAsset	8866000
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5500000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26460000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24443000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	192000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	360000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-2774000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2582000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	359000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-65147000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-36259000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-448000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-706000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137703000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	209520000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72108000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	172555000
	mgtx	Stock Issued Under License Agreement StockIssuedUnderLicenseAgreement	1165000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	7484000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	3184000
	mgtx	Lease Obligations In Exchange Of Right Of Use Assets LeaseObligationsInExchangeOfRightOfUseAssets	-1793000
	mgtx	Lease Obligations In Exchange Of Right Of Use Assets LeaseObligationsInExchangeOfRightOfUseAssets	-4123000
	us-gaap	Asset Retirement Obligation Period Increase Decrease AssetRetirementObligationPeriodIncreaseDecrease	9000
	us-gaap	Interest Paid Net InterestPaidNet	75000
	us-gaap	Interest Paid Net InterestPaidNet	35000
	mgtx	No.Of Programs In Clinical Development No.OfProgramsInClinicalDevelopment	6
	mgtx	No.Of Distinct Areas Of Unmet Medical Need No.OfDistinctAreasOfUnmetMedicalNeed	3
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405600000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36100000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72100000
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
	mgtx	No.Of Distinct Areas Of Unmet Medical Need No.OfDistinctAreasOfUnmetMedicalNeed	3
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405600000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36100000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72100000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations and tax incentive receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Additionally, the Company has made estimates of the impact of the COVID-19 pandemic within the condensed consolidated financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2081000
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1814000
	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	9000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	84000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	74000
	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	-75000
	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	9000
CY2022Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2099000
CY2021Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1897000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations and tax incentive receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Additionally, the Company has made estimates of the impact of the COVID-19 pandemic within the condensed consolidated financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2081000
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1814000
	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	9000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	84000
	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	74000
	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	-75000
	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	9000
CY2022Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2099000
CY2021Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1897000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9244830
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7557926
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9244830
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7557926
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	148049000
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	136921000
CY2022Q2	mgtx	Other Investment Ownership Percentage OtherInvestmentOwnershipPercentage	0.03
CY2022Q2	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	6656000
CY2022Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	6665000
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	148049000
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	136921000
CY2022Q2	mgtx	Other Investment Ownership Percentage OtherInvestmentOwnershipPercentage	0.03
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	1500000
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	1500000
CY2022Q2	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	6656000
CY2022Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	6665000
CY2022Q2	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	16523000
CY2021Q4	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	12524000
CY2022Q2	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	1421000
CY2021Q4	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	2077000
CY2022Q2	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	1050000
CY2021Q4	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	6029000
CY2022Q2	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	735000
CY2021Q4	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	858000
CY2022Q2	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	726000
CY2021Q4	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	1735000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	721000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1018000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	364000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	456000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23572000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27586000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5924690
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.16
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1419400
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.10
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18065
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.61
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7034233
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M26D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4181119
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.92
CY2022Q2	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	16523000
CY2021Q4	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	12524000
CY2022Q2	mgtx	Accrued Liabilities Accrued Manufacturing Costs Expense AccruedLiabilitiesAccruedManufacturingCostsExpense	2032000
CY2021Q4	mgtx	Accrued Liabilities Accrued Manufacturing Costs Expense AccruedLiabilitiesAccruedManufacturingCostsExpense	2889000
CY2022Q2	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	1421000
CY2021Q4	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	2077000
CY2022Q2	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	1050000
CY2021Q4	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	6029000
CY2022Q2	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	735000
CY2021Q4	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	858000
CY2022Q2	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	726000
CY2021Q4	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	1735000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	721000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1018000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	364000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	456000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23572000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27586000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5924690
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.16
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1419400
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.10
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18065
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	291792
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.82
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7034233
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M26D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4181119
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.92
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M7D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2802
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2770
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4200000
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4300000
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4300000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11000000.0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9700000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.64
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7303000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5203000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14881000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10020000
	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2802
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2770
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4200000
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4300000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11000000.0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9700000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.64
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1285000
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	38000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23721000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24765000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	27645000
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	4000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	12000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7303000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5203000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14881000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10020000
	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2600000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2400000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	275000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	313000
CY2022Q2	mgtx	Finance Lease Cost FinanceLeaseCost	275000
CY2021Q2	mgtx	Finance Lease Cost FinanceLeaseCost	313000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1341000
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1285000
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	38000
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	243000
CY2022Q2	us-gaap	Lease Cost LeaseCost	1654000
CY2021Q2	us-gaap	Lease Cost LeaseCost	1841000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	568000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	622000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
	mgtx	Finance Lease Cost FinanceLeaseCost	569000
	mgtx	Finance Lease Cost FinanceLeaseCost	623000
	us-gaap	Operating Lease Cost OperatingLeaseCost	2675000
	us-gaap	Operating Lease Cost OperatingLeaseCost	2422000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	76000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	433000
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2600000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	313000
CY2022Q2	mgtx	Finance Lease Cost FinanceLeaseCost	275000
CY2021Q2	mgtx	Finance Lease Cost FinanceLeaseCost	313000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1341000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P176Y2M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P176Y8M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000
CY2021Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1365000
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1258000
CY2021Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3003000
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	8000
	us-gaap	Operating Lease Payments OperatingLeasePayments	2444000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1793000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4123000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
	us-gaap	Lease Cost LeaseCost	3320000
	us-gaap	Lease Cost LeaseCost	3478000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21538000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22782000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	22693000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23721000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24765000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	27645000
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	4000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	12000
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P176Y2M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P176Y8M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000
CY2021Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1365000
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1258000
CY2021Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3003000
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	8000
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	8000
	us-gaap	Operating Lease Payments OperatingLeasePayments	2735000
	us-gaap	Operating Lease Payments OperatingLeasePayments	2444000
	mgtx	Finance Lease Payments FinanceLeasePayments	1000
	mgtx	Finance Lease Payments FinanceLeasePayments	1000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1793000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4123000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2692000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	4000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5511000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5378000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5336000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2692000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	4000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5511000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5378000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5336000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5064000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2022Q2	mgtx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4634000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	28615000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5922000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	22693000
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	4000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2022Q2	mgtx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4634000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	28615000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5922000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	22693000
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	4000

Files In Submission

Name	View Source	Status
0001558370-22-013192-index-headers.html	Edgar Link	pending
0001558370-22-013192-index.html	Edgar Link	pending
0001558370-22-013192.txt	Edgar Link	pending
0001558370-22-013192-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgtx-20220630.xsd	Edgar Link	pending
mgtx-20220630x10q.htm	Edgar Link	pending
mgtx-20220630xex31d1.htm	Edgar Link	pending
mgtx-20220630xex31d2.htm	Edgar Link	pending
mgtx-20220630xex32d1.htm	Edgar Link	pending
mgtx-20220630xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
mgtx-20220630_cal.xml	Edgar Link	unprocessable
mgtx-20220630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
mgtx-20220630_def.xml	Edgar Link	unprocessable
mgtx-20220630_pre.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mgtx-20220630x10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGTX
MeiraGTx Holdings plc Stock $mgtx

2022 Q3 Form 10-Q Financial Statement

#000155837022013192 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGTX MeiraGTx Holdings plc Stock $mgtx

2022 Q3 Form 10-Q Financial Statement

#000155837022013192 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGTX
MeiraGTx Holdings plc Stock $mgtx